Prenetics (PRE) Q1 2026 Earnings Call Transcript

Prenetics reported Q1 revenue of $36 million, up about 334% year over year, driven by IM8 revenue of $33.8 million, and raised full-year 2026 IM8 guidance to $190 million-$210 million from $180 million-$200 million. IM8 gross margin improved to 64.3%, active subscribers reached 82,000, and 93% of segment revenue came from subscriptions, though operating loss widened to $8.9 million and adjusted EBITDA loss was $5.6 million due to higher marketing spend. The company also sold its 510 Bitcoin for $41.3 million, has repurchased $19 million under its buyback authorization, and outlined three Q4 product launches that could add incremental upside.

Analysis

PRE is transitioning from a story stock to a payments-quality subscription compounder, and the market is likely underestimating how much quarterly billing changes the economics. The step-up in AOV and repeat mix should mechanically lift reported revenue durability while lowering churn sensitivity, because more of the customer base is now pre-committed before the product cycle can break. That creates a second-order benefit for paid media efficiency: higher upfront cash collection funds more aggressive CAC scaling without a proportional working-capital drag.

The bigger competitive implication is not just that IM8 is winning share; it is that the category’s economics are being redefined around clinical validation + athlete-led distribution + AI creative throughput. That combination raises the bar for DTC supplement peers that rely on either performance marketing or brand alone. The disclosed move toward channel diversification also matters: if TikTok/YouTube/AppLovin become incremental rather than replacement channels, META loses some leverage over PRE’s growth ceiling, which is bullish for margin sustainability and reduces single-platform fragility.

The hidden risk is that the current valuation setup may be extrapolating cohort curves too aggressively into 2027-28 before the new customer acquisition engine proves it can scale beyond the existing Meta playbook. The next 1-2 quarters matter more than the full-year guide: if April/May momentum slows as ad saturation rises or if quarterly subscribers prove less incremental than claimed, the market could quickly de-rate the growth multiple. The Bitcoin liquidation is also a signal that management wants maximum flexibility for buybacks and marketing, but it removes a non-core optionality lever that had been visually supporting the balance sheet narrative.

Key Decisions for Investors

• Long PRENW outright into the next 1-2 quarters if you believe April/May momentum is sustainable; use a tight stop if Q2 revenue comes in below the low end of guidance, because the stock is now priced more like a durable growth compounder than a binary story.
• If liquid options are available, buy PRE call spreads out 3-6 months to express upside from continued cohort acceleration while limiting downside if paid acquisition efficiency normalizes.
• Pair trade: long PRE / short a basket of slower-growth DTC health names with weaker retention disclosure (e.g., sector peers with lower repeat mix) to isolate the cohort-economics premium.
• Fade META platform concentration risk only indirectly: if PRE channel diversification works, it is incremental evidence for the broader DTC ad ecosystem, so prefer long APP over short META if you want to own the ad-tech beneficiaries of spend migration.
• Trim into strength if the stock re-rates ahead of Q2 print on assumption of uninterrupted 30%+ sequential growth; the key catalyst window is the next earnings release, not the Q4 product launches.